Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 21, 2022

AAPS to Provide Scientific Programming Oversight for Interphex

AAPS will exclusively advise RX Global on scientific focus areas for Interphex 2023, which is set to take place at the Javits Center in New York City next spring.

The American Association of Pharmaceutical Scientists (AAPS), a non-profit, professional society of 7,000 pharmaceutical scientists, announced on Oct. 19, 2022 that it would be the exclusive authority advising RX Global on scientific focus areas for Interphex, an 8,000 person event focusing on the commercial contracting space. AAPS and RX are now developing plans for the 2023 Interphex meeting, which is set to take place April 25-27, 2023, at the Javits Center in New York City.

“This is an important step for us in pursuing our mission of bringing scientists together to advance cures and therapies that will help patients around the world,” said Patrick Sinko, president, AAPS, in an agency press release. “We are going to support RX in creating a scientific experience at Interphex that helps industry professionals look into the future while solving today’s problems.”

“The collaboration with AAPS is an important next chapter for Interphex,” said Marie Brown, group vice-president, RX, in the release. “Interphex has traditionally been an event primarily focused on product discovery and finding solutions to effectively develop and manufacture quality products. We are excited that AAPS will elevate and expand the content to attract and satisfy the educational needs of research scientists and provide that important link between science and commercialization.”

Source: AAPS


Related to this article

The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.